Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
AB-106 will be administered once a day. Each treatment cycle is defined as 21 days of
continuous medication. Dosing will continue until any of the following conditions are met:
disease progression, intolerable drug-related adverse events, researchers recommend
discontinuation of treatment, withdrawal of informed consent, pregnancy during the study, use
of other anti-tumor therapy, loss of follow-up, death and other causes, whichever occurs
first.
The study includes a screening period, treatment period, safety follow-up and long-term
follow-up.